Covance Clinical Research Unit
Madison, Wisconsin, 53704, United States
NCT Number: NCT03748628
A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of [14C]EDP-305 in healthy male subjects.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Madison, Wisconsin, 53704, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
[14C]EDP-305
Time frame: Up to 9 days
Time frame: Up to 9 days
Time frame: Up to 9 days
Time frame: Up to 9 days
Time frame: Up to 9 days
Time frame: Up to 9 days
Enanta Pharmaceuticals, Inc
Industry
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-305 Following a Single Oral Dose in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05039450
Digestive System Diseases, Fatty Liver
Chandler, Arizona, United States
View Trial DetailsNCT05338034
Digestive System Diseases, Fatty Liver
Texas City, Texas, United States
View Trial DetailsNCT06195943
Behavior, Digestive System Diseases
Hershey, Pennsylvania, United States
View Trial DetailsNCT04591106
Digestive System Diseases, Fatty Liver
Los Angeles, California, United States
View Trial Details